INVESTER I LYTIX BIOPHARMA MED ENDAVU: Køb LYTIX BIOPHARMA ($6BG) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i LYTIX BIOPHARMA, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Lytix Biopharma ASA is a clinical-stage biotechnology company focused on developing cancer immunotherapies that activate and strengthen the patient’s immune response against tumors. Its principal product candidate, ruxotemitide, is an oncolytic molecule designed for intratumoral administration and is being developed for conditions including melanoma, basal cell carcinoma, and advanced soft-tissue sarcoma. The company is also evaluating its technology in combination-treatment settings, including studies pairing ruxotemitide with pembrolizumab. Lytix Biopharma ASA operates within the pharmaceutical biotechnology sector, concentrating on research, clinical development, and the potential commercialization or licensing of therapies for cancer and related medical applications. Headquartered in Oslo, Norway, the company represents the clinical-development segment of the healthcare market, where specialized biotechnology firms advance targeted therapeutic platforms toward regulatory approval and potential use by hospitals, oncology specialists, and pharmaceutical partners. Its activities span drug development, clinical research, intellectual-property management, and collaboration across the international oncology ecosystem.